Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma.

Journal of surgical oncology - 1 Jun 2011

Teng Hao-Wei, Wang Hsei-Wei, Chen Wei-Ming, Chao Ta-Chung, Hsieh Yao-Yu, Hsih Chi-Hsiu, Tzeng Cheng-Hwai, Chen Paul Chih-Hsueh, Yen Chueh-Chuan

Abstract excerpt

BACKGROUND: We aimed to study the prevalence and prognostic influence of epidermal growth factor receptor (EGFR) and its downstream effectors in synovial sarcoma (SS). OBJECTIVES AND METHODS: The tissue blocks from 30 patients were obtained. Expression of EGFR and phosphatase and tensin homolog (PTEN) were examined by immunohistochemistry, and mutation status of v-Ki-ras2 Kirsten rat sarcoma viral oncogene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Multivariate Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinases

Share to PTEN Phosphohydrolase

Share to ras Proteins

Share to Sequence Analysis, Protein

Share to Soft Tissue Neoplasms

Share to Survival Analysis

Source

Identifiers

PMID: 21240992
DOI: 10.1002/jso.21852

Genes

PTEN
EGFR
BRAF
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma.PMID 21240992Read ↗

Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.Semantic proximity Read ↗

Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma.Semantic proximity Read ↗

BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma.Semantic proximity Read ↗

Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors.Semantic proximity Read ↗

Next generation sequencing in synovial sarcoma reveals novel gene mutations.Semantic proximity Read ↗

Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.Semantic proximity Read ↗

Expression of receptor tyrosine kinases epidermal growth factor receptor and HER‐2/<i>neu</i> in synovial sarcomaSemantic proximity Read ↗

The PTEN Tumor Suppressor Gene in Soft Tissue SarcomaSemantic proximity Read ↗

IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1Semantic proximity Read ↗

Correlation of URGCP Gene Expression in Neurotrophic Tyrosin Kinase 1,2,3 and MAPK Signal Transduction Pathways as a New Approach in SarcomasSemantic proximity Read ↗

Molecular Characterization of Synovial Sarcoma in Children and Adolescents: Evidence of Akt ActivationSemantic proximity Read ↗

Intrathoracic synovial sarcoma with BRAF V600E mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.